Petros pharmaceuticals partners with innolitics, a leading software-as-a-medical-device developer

With more than $10m in cash, and a significantly reduced burn rate, the company is positioned to fully fund the development of its technology platform. new york, ny / access newswire / may 20, 2025 / petros pharmaceuticals, inc. (nasdaq:ptpi) ("petros" or the "company"), a company focused on expanding consumer access to medication through over the counter ("otc") drug development programs, today announces its partnership with innolitics, a leading developer in the software-as-a-medical device space.
PTPI Ratings Summary
PTPI Quant Ranking